Biovie (BIVI) EPS (Basic) (2013 - 2026)

Biovie (BIVI) posted EPS (Basic) of -$0.7 for Q1 2026, up 8.83% sequentially from -$0.77 in Q4 2025, and up 53.63% YoY from -$0.45 in Q1 2025.

Biovie (BIVI) EPS (Basic) (2013 - 2026) Analysis & Trends

Biovie has reported EPS (Basic) for 12 years, with the latest figure at -$0.7 in Q1 2026.

Quarterly EPS (Basic) rose 53.63% year-over-year to -$0.7 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.65 (up 74.71% YoY) and the FY2025 annual result came in at -$12.12, up 83.4% from the prior year.
EPS (Basic) climbed to -$0.7 in Q1 2026 per BIVI's latest filing, from -$0.77 in the prior quarter.
Over five years, EPS (Basic) peaked at -$0.7 in Q1 2026 and troughed at -$50.33 in Q4 2022.
A 5-year average of -$18.83 and a median of -$19.99 in 2024 frame the typical range for EPS (Basic).
The widest YoY moves for EPS (Basic): up 96.91% in 2022, down 132.04% in 2022.
Over 5 years, EPS (Basic) stood at -$50.33 in 2022, then jumped by 56.27% to -$22.01 in 2023, then jumped by 79.31% to -$4.55 in 2024, then surged by 83.17% to -$0.77 in 2025, then grew by 8.83% to -$0.7 in 2026.
According to Business Quant data, EPS (Basic) over the past three periods registered -$0.7, -$0.77, and -$0.98 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	12.62
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	7.59
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-1.96
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	2.12
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	1.23
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.06
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	0.18
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-0.72
10	Biovie	13.55 Mn	13.55 Mn	-	-0.78

Download Data